NCT06114004View on ClinicalTrials.gov

Selinexor Plus Gemcitabine in Selected Advanced Soft-tissue Sarcoma (SeliSarc)

PHASE2RecruitingINTERVENTIONAL
Enrollment

88

Participants

Timeline

Start Date

September 28, 2023

Primary Completion Date

May 31, 2026

Study Completion Date

May 31, 2026

Conditions
Sarcoma,Soft Tissue
Interventions
DRUG

Selinexor 20 MG

After having completed the Phase I part, the recommended dose for Phase II is 60mg Selinexor

DRUG

Gemcitabine

Gemcitabine will be given at the dose 1200 mg/m2 (10 mg/m2/min) days 1 and 8 every 21 days.

Trial Locations (11)

20014

NOT_YET_RECRUITING

Hospital Universitario de Donostia, Donostia / San Sebastian

28009

NOT_YET_RECRUITING

Hospital General Universitario Gregorio Marañón, Madrid

28040

RECRUITING

Hospital Clínico San Carlos, Madrid

RECRUITING

Hospital Universitario Fundación Jiménez Díaz, Madrid

28046

RECRUITING

Hospital Universitario La Paz, Madrid

30120

NOT_YET_RECRUITING

Hospital Clínico Universitario Virgen de la Arrixaca, Murcia

38320

NOT_YET_RECRUITING

Hospital Universitario de Canarias, Santa Cruz de Tenerife

46010

NOT_YET_RECRUITING

Hospital Clinico Universitario Valencia, Valencia

50009

RECRUITING

Hospital Universitario Miguel Servet, Zaragoza

08025

RECRUITING

Hospital de la Santa Creu i Sant Pau, Barcelona

08035

RECRUITING

Hospital Universitario Vall d'Hebron, Barcelona

All Listed Sponsors
lead

Asociación Europea y Latinoamericana SELNET para la Investigación en Sarcomas

OTHER